RT Journal Article
SR Electronic
T1 Ethnically diverse mutations in <em>PIEZO1</em> associate with SARS-CoV-2 positivity
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.06.01.20119651
DO 10.1101/2020.06.01.20119651
A1 Cheng, C.W.
A1 Deivasikamani, V.
A1 Ludlow, M.J.
A1 De Vecchis, D.
A1 Kalli, A.C.
A1 Beech, D.J.
A1 Sukumar, P.
YR 2020
UL http://medrxiv.org/content/early/2020/06/03/2020.06.01.20119651.abstract
AB COVID-19, caused by the SARS-CoV-2 virus, carries significant risk of mortality and has spread globally with devastating societal consequences. Endothelial infection has been identified as a feature of the disease and so there is motivation to determine the relevance of endothelial membrane mechanisms affecting viral entry and response. Here, through a study of patient data in UK Biobank released on 16 April 2020, we suggest relevance of PIEZO1, a non-selective cation channel protein that both mediates endothelial responses to mechanical force and unusually indents the cell membrane. PIEZO1 notably has roles that may also be relevant in red blood cell function, pulmonary inflammation, bacterial infection and fibrotic auto-inflammation. We provide evidence that single nucleotide polymorphisms (SNPs) in the gene encoding PIEZO1 are more common in individuals who test positive for SARS-CoV-2 regardless of pre-existing hypertension, myocardial infarction, stroke, diabetes mellitus or arthritis. Some of these SNPs are more common in African and Caribbean populations, which are groups that were recently shown to have greater susceptibility to infection. One of the SNPs is a missense mutation that results in an amino acid change in an evolutionarily conserved and previously unexplored N-terminal region PIEZO1. The data support the notion of genetic factors influencing SARS-CoV-2 infection and suggest a specific role for PIEZO1.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported by a Wellcome Trust Investigator Award to DJB, a BHF Daphne Jackson Fellowship to VD and Leeds Cardiovascular Endowment funds for support of CWCAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:UK BiobankAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe data analysed are available to the registered users through UK Biobank https://www.ukbiobank.ac.uk/